Takeda buys Ariad Pharmaceuticals for $ 5.2 billion

Acquisition significantly enhances Takeda's global oncology portfolio

Premium

BS B2B Bureau Osaka, Japan

Last Updated : Jan 17 2017 | 11:16 AM IST

Japan’s Takeda Pharmaceutical Company Limited has acquired the US-based Ariad Pharmaceuticals Inc for an enterprise value of approximately $5.2 billion. Attractive value drivers include two very innovative medicines (Iclusig & brigatinib), an exciting early stage pipeline and cost synergies.

Christophe Weber, president and chief executive officer of Takeda, commented, “This is a very exciting time for Takeda as we will broaden our haematology portfolio and transform our global solid tumour franchise through the addition of two innovative targeted therapies. Opportunities to acquire such high-quality, complementary targeted therapies do not come often, and we are very excited about the potential for this

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in